Risk of Hepatitis B Exacerbation is Low After Transcatheter Arterial Chemoembolization Therapy for Patients with HBV-related Hepatocellular Carcinoma: Report of a Prospective Study
- 1 October 2005
- journal article
- clinical trial
- Published by Wolters Kluwer Health in The American Journal of Gastroenterology
- Vol. 100 (10), 2194-2200
- https://doi.org/10.1111/j.1572-0241.2005.00232.x
Abstract
Systemic chemotherapy may lead to immune suppression and possible reactivation of hepatitis B virus (HBV), suggesting prophylactic antiviral therapy in cancer patients with HBV. Transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) is not a systemic chemotherapy, but has been partially associated with HBV reactivation. The aim of this study was to evaluate whether TACE aggravates HBV hepatitis in patients with HBV-related HCC. Eighty-nine patients with HBV-related HCC were studied prospectively. Patients treated with TACE were enrolled in the case group (n = 69), and patients in follow-up or awaiting treatment were enrolled in the control group (n = 20). TACE was performed with doxorubicin (20-60 mg) and lipiodol (2-20 mL). Three (4.3%) patients in the TACE group and 2 (10%) patients in the control group showed HBV reactivation (p= 0.334). A twofold or more increase in serum HBV DNA was detected in 21 (30.4%) patients in the TACE group and 4 (20%) patients in the control group (p= 0.361). Exacerbation of viral hepatitis B was found in 4 (5.8%) patients in the TACE group and no patients in the control group, but the difference between the two rates was not statistically significant (p= 0.271). Three of the four reactivated patients showed spontaneous recovery within 1 month, and one showed tumor-progression-related exacerbation. One session of TACE using doxorubicin and lipiodol does not significantly aggravate HBV hepatitis in patients with HBV-related HCC.Keywords
This publication has 28 references indexed in Scilit:
- Lamivudine for the Prevention of Hepatitis B Virus Reactivation in Hepatitis B s-Antigen Seropositive Cancer Patients Undergoing Cytotoxic ChemotherapyJournal of Clinical Oncology, 2004
- Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignanciesJournal of Viral Hepatitis, 2004
- Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measuresJournal of Viral Hepatitis, 2004
- Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphomaHepatology, 2003
- Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipientsHepatology, 2002
- Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy — pathogenesis and managementReviews in Medical Virology, 2001
- Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factorsJournal of Medical Virology, 2000
- The 20th United States-Japan joint hepatitis panel meetingHepatology, 2000
- Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapyGastroenterology, 1991
- Reactivation of Chronic Hepatitis B Virus Infection by Cancer ChemotherapyAnnals of Internal Medicine, 1982